Document:

CONFIDENTIAL
      TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED
      AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION.

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    ASSET
      PURCHASE AGREEMENT

    

    This
      Asset Purchase Agreement is entered into as of August 3, 2006, between Inyx,
      Inc., a Nevada corporation or its nominee ("Buyer"),
      and
      Advanced Medical Optics, Inc., a Delaware corporation, on behalf of itself
      and
      its subsidiaries (collectively, "Seller").
      

    

    R
      E C I T A L S

    

    WHEREAS,
      Seller owns certain assets more particularly described in this Agreement, used
      by it in the Seller’s business (the “Business”)
      of
      selling the eye care products listed in Schedule 1 to this Agreement (the
“Products”);
      and

    

    WHEREAS,
      Seller desires to sell, and Buyer desires to buy, those assets and Buyer is
      willing to assume certain specific obligations and liabilities, for the
      consideration and on the terms and conditions described herein.

     

    A
      G R E E M E N T

    

    In
      consideration of the mutual promises contained herein and intending to be
      legally bound, the parties agree as follows:

    

    ARTICLE
      1

    PURCHASE AND
      SALE OF ASSETS

     

    
      	 	
              1.1

            	
              Transfer
                of Assets. Subject
                to the terms and conditions of this Agreement, on the Closing Date
                (as
                defined herein), Seller will sell to Buyer, and Buyer will purchase
                from
                Seller, all of Seller's right, title and interest in and to all of
                the
                following assets, which are used in or are related to the Business
                (the
                "Assets"). The Assets include only the
                following:

            

    

     

    
      	 	
              1.1.1

            	
              Inventory. All
                inventory of the Products at all locations world wide, including
                inventory
                at third party logistics sites (including finished goods, work-in-process
                and raw materials and returned Product; collectively, the "Inventory"),
                a
                list of which as of July 25, 2006 is set forth in
                Schedule 1.1.1;

            

    

     

    
      	 	
              1.1.2

            	
              Intellectual
                Property.
                Seller’s
                interest in the following assets listed in Schedule 1.1.2, as well
                as the
                good will associated therewith, in each case as used solely in the
                Business (collectively, the “Intellectual Property”): patents, trademarks
                and trade names, trademark and trade name registrations, service
                marks and
                service mark registrations, copyrights and copyright registrations,
                the
                applications therefor and the licenses with respect thereto, and
                the
                manufacturing formulae, specifications, processes, artwork, proprietary
                molds and similar proprietary equipment but specifically excluding
                all
                “Advanced Medical Optics” and “AMO” marks, including any and all
                trademarks or service marks, trade names, slogans or other like property
                which includes the name “Advanced Medical Optics” or “AMO”, or any
                derivative thereof and Seller's logo or any derivative
                thereof;

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    
      	 	
              1.1.3

            	
              Sales,
                Marketing and Promotion Materials.
                All
                of Seller's historical and current sales data material and information,
                customer lists, wholesaler lists, distribution lists, supplier lists,
                mailing lists, catalogues, brochures, sales literature, promotional
                marketing material, advertising material and other selling material
                pertaining to the Products, including without limitation all market
                research, competitive intelligence and promotional material, in each
                case
                solely related to the Business;

            

    

     

    
      	 	
              1.1.4

            	
              Books
                and Records.
                All
                books and records and all files, documents, papers and agreements
                (including, but not limited to, those contained in computerized storage
                media) pertaining to the Assets, the Assumed Liabilities or otherwise
                to
                the Business (other than Seller’s corporate books and records), subject to
                Seller retaining copies of the same, if and as it so
                chooses;

            

    

     

    
      	 	
              1.1.5

            	
              Assigned
                Contracts.
                All
                rights of Seller under all contracts, guarantees and warranties from
                third
                parties pertaining exclusively to the Products and listed on Schedule
                1.1.5, subject to the approval of the other parties to such contracts
                (the
                "Assigned Contracts"); and

            

    

     

    
      	 	
              1.1.6

            	
              Product
                Registrations.
                All
                Product Registrations (and applications therefor) exclusively related
                to
                the Business and listed on Schedule 1.1.6 if and to the extent
                transferable. “Product Registrations” means all licenses, permits,
                certificates and other authorizations and approvals required to market
                any
                Product as conducted as of the date of this Agreement under the applicable
                laws of any governmental authority (supranational, national, federal,
                state, local, municipal, judicial, legislative, executive or regulatory)
                in the countries in which Products are sold.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    The
      Assets shall include all Inventory that is acquired by Seller between July
      25,
      2006 and the Closing Date, and shall exclude any Inventory that is disposed
      of,
      sold or consumed between July 25, 2006 and the Closing Date in the ordinary
      course of business. Buyer shall arrange for transfer of all tangible assets,
      at
      Buyer’s own expense, within sixty (60) days of execution of this Agreement, and
      shall bear all third party costs incurred by Seller in connection with Seller’s
      assistance provided pursuant to Article 6 of this Agreement. 

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        4

        
          

        

      

      
        
        

      

    

    ARTICLE
      2

    CLOSING/PURCHASE
      PRICE/

    ASSUMPTION
      OF LIABILITIES

    

    
      	 	
              2.1

            	
              The
                Closing.
                The
                Closing will take place at the offices of the Seller, at 10:00 a.m.
                Pacific Time on August 31, 2006, or such later date as the parties
                shall
                mutually agree to in writing (the “Closing Date”). 

            

    

     

    
      	 	
              2.2

            	
              Purchase
                Price.
                Subject
                to the terms and conditions of this Agreement, Buyer agrees to acquire
                the
                Assets from Seller, and to pay U.S.$3,750,000 in cash (the "Purchase
                Price") as follows:

            

    

     

    
      	 	
              2.2.1

            	
              A
                cash payment of US$750,000 upon execution hereof (the “Initial Payment”);
                and

            

    

     

    
      	 	
              2.2.2

            	
              A
                closing payment in the amount of US$3,000,000 (the “Closing Payment”) on
                the Closing Date

            

    

     

    
      	 	
              2.3

            	
              Payments
                to Seller.
                Buyer
                shall pay the Initial Payment and the Closing Payment by wire transfer
                in
                immediately available funds to an account designated by Seller on
                the
                execution hereof. The Initial Payment shall be retained by Seller
                as a
                non-refundable deposit unless the Seller was in material breach of
                a
                representation or warranty set forth in Article 4 of this Agreement
                on the
                date hereof, as determined by the dispute resolution process set
                forth in
                Section 9.9 of this Agreement.

            

    

     

    
      	 	
              2.4

            	
              Instruments
                of Conveyance and Transfer.
                On
                the Closing Date, Seller shall execute and deliver or cause to be
                delivered to Buyer (a) the Bill of Sale in the form attached as
                Exhibit B, (b) the Assignment and Assumption Agreement in the form
                attached as Exhibit A, and (c) such other documents as may be reasonably
                requested by Buyer in order to carry out the transactions contemplated
                by
                this Agreement.

            

    

     

    
      	 	
              2.5

            	
              Assumption
                of Certain Liabilities.
                On
                the Closing Date, Buyer shall execute and deliver to Seller the Assignment
                and Assumption Agreement, pursuant to which, Buyer shall assume and
                agree
                to pay, perform and discharge when due, the liabilities and obligations
                of
                Seller arising out of the Business as follows: (the “Assumed
                Liabilities”):

            

    

     

    
      	 	
              2.5.1

            	
              Contracts. Liabilities
                or obligations of Seller which arise after the Closing Date under
                the
                terms of the Assigned Contracts;
                and

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        5

        
          

        

      

      
        
        

      

    

    
      	 	
              2.5.2

            	
              Liabilities
                Post-Closing.
                All liabilities or obligations for Losses (as defined below) related
                to
                the Assets that are not Retained Liabilities (as defined
                below).

            

    

     

    
      	 	
              2.6

            	
              Conditions
                of Closing. The
                respective obligations of the Buyer and the Seller to consummate
                the
                transactions contemplated by this Agreement are subject to the condition
                that no government order or law makes illegal or enjoins or prevents
                the
                consummation of the transactions contemplated by this Agreement.
                In
                addition, the obligation of the Buyer to consummate the transactions
                contemplated by this Agreement is subject to the conditions that
                (a) the
                Seller shall have performed in all material respects its agreements
                and
                obligation contained in this Agreement required to be performed by
                it at
                or before the Closing Date, and (b) the representations and warranties
                of
                the Seller set forth in Article 4 of this Agreement shall have been
                true
                and correct in all material respects when made and shall be true
                and
                correct in all material respects as of the Closing Date, as if made
                on the
                Closing Date, except for changes contemplated or permitted by this
                Agreement and those representations and warranties that address matters
                as
                of a particular date, which need be true in all material respects
                only as
                of such date. The obligation of the Seller to consummate the transactions
                contemplated by this Agreement is subject to the conditions that
                (x) the
                Seller shall have performed in all material respects its agreements
                and
                obligations contained in this Agreement required to be performed
                by it at
                or before the Closing Date and (y) the representations and warranties
                of
                the Seller set forth in Article 5 of this Agreement shall have been
                true
                and correct in all material respects as of the Closing Date, as if
                made on
                the Closing Date, except for changes contemplated or permitted by
                this
                Agreement and those representations and warranties that address matters
                as
                of a particular date, which need be true in all material respects
                only as
                of such date. At the Closing Date, the parties shall exchange
                certificates, signed by a senior officer of each entity, certifying
                as to
                the fulfillment of the foregoing
                conditions.

            

    

     

    ARTICLE
      3

    TRADEMARK
      LICENSE

     

    
      	 	
              3.1

            	
              License.
                Subject
                to the terms and conditions of this Agreement, Buyer licenses to
                Seller as
                of the Closing Date the non-exclusive, worldwide, perpetual,
                sublicensable, fully paid-up, royalty-free right to use the LENS
                PLUS
                trademark on saline solutions and the HYDROCARE
                trademark on solutions and tablets for disinfecting, cleaning, wetting,
                storing and/or rinsing contact lenses. Collectively, LENS PLUS and
                HYDROCARE
                shall be referred to as the “Licensed Marks”, and all of the
                aforementioned goods shall be referred to as the “Licensed
                Products”.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        6

        
          

        

      

      
        
        

      

    

    
      	 	
              3.2

            	
              Product
                Quality of Licensed Products.
                Seller
                agrees that after the Closing Date the quality of all Licensed Products
                in
                connection with the Licensed Marks shall conform to applicable minimum
                standards. Buyer agrees that the current quality of all Licensed
                Products
                is exceptional, and shall place no requirements on Seller unless
                the
                quality of the Licensed Products falls substantially below the present
                quality. 

            

    

     

    ARTICLE
      4

    REPRESENTATIONS
      AND WARRANTIES OF SELLER

     

    Seller
      represents, warrants and agrees as follows:

     

    
      	 	
              4.1

            	
              Organization,
                Corporate Power and Authority.
                Seller
                is duly organized and validly existing under the laws of the State
                of
                Delaware.

            

    

     

    
      	 	
              4.2

            	
              Authorization
                of Agreements.
                The
                execution, delivery and performance by Seller of this Agreement have
                been
                duly authorized by all necessary corporate action by Seller. This
                Agreement has been duly executed and delivered by Seller and constitutes
                the legal, valid and binding obligation of Seller, enforceable against
                Seller in accordance with its
                terms.

            

    

     

    
      	 	
              4.3

            	
              Effect
                of Agreement.
                The
                execution, delivery and performance by Seller of this Agreement will
                not
                violate the charter documents or bylaws of Seller or any material
                indenture, material agreement or other material instrument to which
                Seller
                is a party, or by which Seller or the Assets are bound, or conflict
                with,
                result in a breach of or constitute (with due notice or lapse of
                time or
                both) a default under, any such indenture, agreement or other
                instrument.

            

    

     

    
      	 	
              4.4

            	
              Condition
                of Property.
                Except
                as set forth in Schedule 4.4, Seller has good and marketable title
                to all
                of the Assets, except for liens for taxes not yet due and imperfections
                in
                title, if any, not material in
                amount.

            

    

     

    
      	 	
              4.5

            	
              No
                Brokers or Finders.
                No
                agent, broker, finder, or investment or commercial banker, or other
                Person
                or firm engaged by or acting on behalf of Seller or any of its affiliates
                in connection with the negotiation, execution or performance of this
                Agreement, is or will be entitled to any brokerage or finder's or
                similar
                fee or other commission as a result of this
                Agreement.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        7

        
          

        

      

      
        
        

      

    

    
      	 	
              4.6

            	
              Intellectual
                Property.
                Except
                as set forth in Schedule 4.4, to the best of the Seller’s knowledge,
                Seller is the beneficial owner of or has a valid and subsisting license
                to
                use the Intellectual Property, free and clear of all encumbrances,
                and is
                not a party to or bound by any contract or other obligation whatsoever
                that limits or impairs its ability to sell, transfer, assign or convey
                the
                Intellectual Property. The Seller is not aware of any third party
                claim
                regarding the validity or enforceability of any of the Intellectual
                Property. The Seller is not aware of any third party claim that the
                sale
                of the Products has infringed the intellectual property rights of
                any
                other person 

            

    

     

    ARTICLE
      5

    REPRESENTATIONS
      AND WARRANTIES OF BUYER

     

    Buyer
      represents, warrants and agrees as follows:

     

    
      	 	
              5.1

            	
              Organization,
                Corporate Power and Authority.
                Buyer
                is duly organized and validly existing under the laws of the State
                of
                Nevada.

            

    

     

    
      	 	
              5.2

            	
              Authorization
                of Agreement.
                The
                execution, delivery and performance by Buyer of this Agreement have
                been
                duly authorized by all necessary corporate action by Buyer. This
                Agreement
                has been duly executed and delivered by Buyer and constitutes the
                legal,
                valid and binding obligation of Buyer, enforceable against Buyer
                in
                accordance with its terms.

            

    

     

    
      	 	
              5.3

            	
              Effect
                of Agreement.
                The
                execution, delivery and performance by Buyer of this Agreement, will
                not
                violate the charter documents or bylaws of Buyer or any material
                indenture, material agreement or other material instrument to which
                Buyer
                is a party, or by which Buyer or its properties or assets are bound,
                or
                conflict with, result in a breach of or constitute (with due notice
                or
                lapse of time or both) a default under, any such indenture, agreement
                or
                other instrument.

            

    

     

    
      	 	
              5.4

            	
              No
                Brokers or Finders.
                No
                agent, broker, finder or investment or commer-cial banker, or other
                Person
                or firm engaged by or acting on behalf of Buyer or its affiliates
                in
                connection with the negotiation, execution or performance of this
                Agreement is or will be entitled to any broker's or finder's or similar
                fees or other commissions as a result of this
                Agreement.

            

    

     

    
      	 	
              5.5

            	
              Transfer
                of Intellectual Property.
                Buyer agrees to take all necessary actions, at Buyer’s sole expense, to
                transfer the legal ownership of the Intellectual Property from Seller
                to
                Buyer. Seller agrees to provide reasonable assistance to Buyer to
                effect
                such transfers. 

            

    

     

    
      	 	
              5.6

            	
              Condition
                of the Business.
                Buyer
                is purchasing the Assets based solely on the results of its inspections
                and investigations and the representations or warranties of Seller
                expressly set forth in this Agreement. In light of these inspections
                and
                investigations and the representations and warranties made to Buyer
                by
                Seller in Article 4 hereof, Buyer is relinquishing any right to any
                claim
                based on any representations and warranties other than those specifically
                set forth in Article 4 hereof. Any claims Buyer may have for breach
                of
                representation or warranty shall be based solely on the representations
                and warranties of Seller set forth in Article 4 hereof. ALL WARRANTIES
                OF
                HABITABILITY, MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE,
                AND
                ALL OTHER WARRANTIES ARISING UNDER THE UNIFORM COMMERCIAL CODE (OR
                SIMILAR
                FOREIGN LAWS), ARE HEREBY WAIVED BY PURCHASER. 

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        8

        
          

        

      

      
        
        

      

    

     

    ARTICLE
      6

    INDEMNIFICATION

     

    
      	 	
              6.1

            	
              Obligations
                of Buyer.
                Buyer
                agrees to indemnify, defend and hold harmless Seller and its directors,
                officers, employees, affiliates, agents and assigns from and against
                any
                and all Losses, directly or indirectly, as a result of, or based
                upon or
                arising from:

            

    

     

    
      	 	
              6.1.1

            	
              Any
                breach of any representation, warranty or covenant of Buyer made
                in this
                Agreement; and

            

    

     

    6.1.2 The
      Assumed Liabilities. 

     

    
      	 	
              6.2

            	
              Obligations
                of Seller.
                Seller
                agrees to indemnify, defend and hold harmless Buyer and its directors,
                officers, employees, affiliates, agents and assigns from and against
                all
                Losses directly or indirectly, as a result of, or based upon or arising
                from:

            

    

     

    
      	 	
              6.2.1

            	
              Any
                breach of any representation, warranty or covenant of Seller made
                in this
                Agreement; 

            

    

     

    
      	 	
              6.2.2

            	
              Any
                Losses related to returns of product sold by Seller and bearing Seller’s
                label, and any Losses related to the Business or the Assets that
                are
                caused by any reckless or malicious act or omission of Seller prior
                to the
                Closing Date (collectively, the “Retained
                Liabilities”).

            

    

     

    
      	 	
              6.3

            	
              Procedures.
                The
                parties agree that the person seeking indemnification (the “Indemnitee”)
                shall only be entitled to such indemnification if:
                

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        9

        
          

        

      

      
        
        

      

    

    
      	 	
              6.3.1

            	
              The
                Indemnitee had, at its own expense, promptly given the person from
                whom
                indemnification is sought (the “Indemnitor”) written notice of such claims
                upon their filing or creation; and 

            

    

     

    
      	 	
              6.3.2

            	
              The
                Indemnitor had been granted the right to take control of the settlement
                and defense of such claims with counsel reasonably acceptable to
                the
                Indemnitee in exchange for the Indemnitor’s written agreement to accept
                the defense and all liability for the claim without reservation.
                

            

    

     

    The
      Indemnitee shall at all times reasonably cooperate in the settlement and defense
      of all claims and shall make available all records, materials and other relevant
      matter reasonably requested by the Indemnitor in connection with such claims.
      No
      party shall have the right to settle any claims in a manner that materially
      diminishes the rights or interests of the other without that party’s prior
      written consent, which shall not be unreasonably withheld or delayed. The
      Indemnitor shall not be liable for any settlement made without its prior written
      consent. * * *. 

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        10

        
          

        

      

      
        
        

      

    

    
      	 	
              6.4

            	
              Limits.
                *
                *
                *.

            

    

     

    
      	 	
              6.5

            	
              Definition
                of Loss. "Loss"
                means any claims, actions, causes of action, judgments, awards, losses,
                costs, and damages, and all debt, liabilities and obligations, whether
                accrued or fixed, known or unknown, absolute or contingent, matured
                or
                unmatured or determined or determinable. NOTWITHSTANDING ANYTHING
                TO THE
                CONTRARY CONTAINED HEREIN, NO PARTY TO THIS AGREEMENT SHALL BE LIABLE
                TO
                OR OTHERWISE RESPONSIBLE TO ANY OTHER PARTY HERETO OR ANY AFFILIATE
                OF ANY
                OTHER PARTY HERETO FOR CONSEQUENTIAL, INCIDENTAL OR PUNITIVE DAMAGES
                OR
                FOR DIMINUTION IN VALUE OR LOST PROFITS THAT ARISE OUT OF OR RELATE
                TO
                THIS AGREEMENT OR THE PERFORMANCE OR BREACH HEREOF OR ANY LIABILITY
                RETAINED OR ASSUMED HEREUNDER.

            

    

     

    ARTICLE
      7

    TRANSITION
      ARRANGEMENTS

     

    
      	 	
              7.1

            	
              Transition
                Arrangements. *
                *
                *

            

    

     

    
      	 	
              7.2

            	
              Analytical
                and Stability Testing.
                *
                *
                *

            

    

     

    
      	 	
              7.3

            	
              Technology
                Transfer. *
                *
                * 

            

    

     

    ARTICLE
      8

    RIGHT
      OF FIRST REFUSAL

     

    
      	 	
              8.1

            	
              Right
                of First Refusal.
                *
                * *

            

    

     

    ARTICLE
      9

    GENERAL

     

    
      	 	
              9.1

            	
              Amendments; Waivers.
                This
                Agreement and any schedule or exhibit attached hereto may be amended
                only
                by agreement in writing of all parties. No waiver of any provision
                nor
                consent to any exception to the terms of this Agreement shall be
                effective
                unless in writing and signed by the party to be bound and then only
                to the
                specific purpose, extent and instance so
                provided.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        11

        
          

        

      

      
        
        

      

    

    
      	 	
              9.2

            	
              Governing
                Law.
                Notwithstanding its place of execution or performance, this Agreement
                shall be governed by and construed in accordance with the laws of
                the
                State of California, irrespective of its laws regarding choice or
                conflict
                of laws.

            

    

     

    
      	 	
              9.3

            	
              No
                Assignment.
                Neither
                this Agreement nor any rights or obliga-tions under it are assignable,
                provided that either party may assign the Agreement or any rights
                or
                obligations hereunder to a parent company or wholly-owned subsidiary
                without any consent or approval of the other
                party.

            

    

     

    
      	 	
              9.4

            	
              Headings.
                The
                descriptive headings of the Articles, Sections and subsections of
                this
                Agreement are for convenience only and do not constitute a part of
                this
                Agreement.

            

    

     

    
      	 	
              9.5

            	
              Counterparts.
                This
                Agreement and any amendment hereto or any other agreement (or docu-ment)
                delivered pursuant hereto may be executed in one or more counterparts
                and
                by different parties in separate counterparts. All of such counterparts
                shall constitute one and the same agreement (or other document) and
                shall
                become effective (unless otherwise provided therein) when one or
                more
                counterparts have been signed by each party and delivered to the
                other
                party.
                

            

    

     

    
      	 	
              9.6

            	
              Publicity
                and Reports.
                Seller
                and Buyer shall coordinate all publicity relating to the transactions
                contemplated by this Agreement and no party shall issue any press
                release,
                publicity statement or other public notice relating to this Agreement,
                or
                the transactions contemplated by this Agreement, without obtaining
                the
                prior consent of the other party. The parties agree to issue a mutually
                agreed press release announcing the transaction hereunder upon execution
                of this agreement to satisfy public filing requirements of
                Buyer.

            

    

     

    
      	 	
              9.7

            	
              Integration.
                This
                Agreement is both a final expression of the parties’ agreement and a
                complete and exclusive statement with respect to all of its terms.
                The
                Exhibits and Schedules referred to in this Agreement are incorporated
                herein and made a part of this Agreement by this reference. This
                Agreement
                supersedes all prior and contemporaneous agreements and communications,
                whether oral, written or otherwise, concerning any and all matters
                contained herein.

            

    

     

    
      	 	
              9.8

            	
              Notices.
                Any
                notice to be given under this Agreement must be in writing and delivered
                either in person, by any method of mail (postage prepaid) requiring
                return
                receipt, or by overnight courier, to the party to be notified at
                its
                address(es) given below, or at any address such party has previously
                designated by prior written notice to the other. Notice shall be
                presumptively deemed to be sufficiently given for all purposes upon
                the
                earlier of: (a) the date of actual receipt; (b) if mailed, three
                calendar
                days after the date of postmark; or (c) if delivered by overnight
                courier,
                the next business day the overnight courier regularly makes deliveries.
                

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        12

        
          

        

      

      
        
        

      

    

    If
      to
      Buyer, notices must be addressed to:

     

    Inyx,
      Inc.

    825
      Third
      Avenue

    40th
      Floor

    New
      York,
      NY 10022 

    Attention:
      Dr. Jack Kachkar   

     

     

    If
      to
      Seller, notices must be addressed to:

     

    Advanced
      Medical Optics, Inc..

    1700
      S.
      St. Andrew

    Santa
      Ana, CA 92705.

    Attention:
      General Counsel

    

    
      	 	
              9.9

            	
              Dispute
                Resolution.
                Unless resolved by the parties within 60 days, any controversy or
                claim
                (whether such claim sounds in contract, tort, or otherwise) arising
                out of
                or relating to this Agreement, or the breach thereof, shall be settled
                by
                final and binding arbitration before an arbitrator at JAMS/Endispute,
                located in Orange County, California, and such arbitration shall
                be
                conducted pursuant to then current rules for arbitration of commercial
                disputes at JAMS/Endispute. Judgment upon the award rendered by the
                arbitrator may be entered in any court having jurisdiction thereof.
                In no
                event shall the arbitrator have any right or power to award punitive
                or
                exemplary damages

            

    

     

    
      	 	
              9.10

            	
              Non-Competition.
                Seller shall not anywhere in the world launch a new product with
                the same
                specifications as any of the Products acquired by Buyer for a * *
                * from
                the Closing Date; provided, however, that it shall not be deemed
                to be a
                violation of this Section 9.10 for the Seller or any of its subsidiaries
                to invest in, own an interest in, or acquire all or a majority of
                the
                stock or assets of, or merge into or be acquired by any party which
                is not
                engaged primarily in the sale of products having the same specifications
                as the Products.

            

    

    
       

      
        	 	
                
                  9.11 

                

              	
                Non-Solicitation. For
                  a period of * * * and after the Closing Date, the Buyer shall not,
                  and
                  shall cause its subsidiaries not to, directly or indirectly, induce
                  or
                  attempt to induce any officers, employees, representatives or agents
                  of
                  the Seller or its subsidiaries to leave the employ of the Seller
                  for
                  employment with the Buyer or its subsidiaries. Similarly, for a
                  period of
                  two years from and after the Closing Date, the Seller shall not,
                  and shall
                  cause its subsidiaries not to, directly indirectly, induce or attempt
                  to
                  induce any officers, employees, representatives or agents of the
                  Buyer or
                  its subsidiaries to leave the employ of the Buyer for employment
                  with the
                  Seller or its subsidiaries. Nothing in this Section 9.11 shall
                  restrict or
                  preclude the Buyer or the Seller or any of their subsidiaries from making
                  generalized searches for employees by the use of advertisements
                  in the
                  media (including trade media) or by engaging search firms to engage
                  in
                  searches that are not targeted or focused on the employees employed
                  by the
                  other party.

              

      

       

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        13

        
          

        

      

      
        
        

      

    

    
      	 	
              9.12

            	
              Tax
                Matters.
                Buyer agrees to prepare or cause to be prepared the final purchase
                price
                allocation among the Assets and to prepare Internal Revenue Service
                Form
                8594 to be provided to Seller by the end of March
                2007.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        14

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF,
      each of
      the parties hereto has caused this Agreement to be executed by its duly
      authorized officers as of the day and year first above written.

     

    

    BUYER

    INYX,
      INC.

    

    

    By:
      /s/ Steve
      Handley                

    Name:
      Steve Handley

    Title:
      President

    

     

    

    SELLER

    ADVANCED
      MEDICAL OPTICS, INC.

    

     

    By:
      /s/ James V.
      Mazzo                

    Name:
      James
      V.
      Mazzo
Title:
      Chairman, President and CEOCONFIDENTIAL
      TREATMENT REQUESTED. CONFIDENTIAL PORTIONS

     OF
      THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY

     FILED
      WITH THE COMMISSION.

     

     

     

    

    

    
 

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    CO-PROMOTION
      AGREEMENT

    

    This
      CO-PROMOTION AGREEMENT (“Agreement”) dated as of April 3, 2006 (the “Effective
      Date”), by and between TEAMM Pharmaceuticals, Inc. a Florida corporation with
      offices located at 2501 Aerial Center Parkway, Morrisville, NC (“TEAMM”) and
      Exaeris, Inc. a Delaware corporation with offices located at 403 Gordon Dr,
      Exton, PA 19341 (“Exaeris”)

    

    WITNESSETH:

    

    WHEREAS,
      TEAMM
      markets and
      promotes the pharmaceutical product MD TurboTM (including any improvements,
      modifications, revisions and anticipated related products, collectively the
      “Product”) to a physician audience which focuses on Primary Care and Respiratory
      specialties. 

    

    WHEREAS, TEAMM
      desires to expand the detailing and
      promotion of the Product to additional physician audiences;

    

    WHEREAS,
      Exaeris
      desires to detail and promote the Product to prescribers
      including * * * (the “Exaeris Prescribers”) other than
      the
      physicians called on by TEAMM
      (the “TEAMM Prescribers”).

    

    NOW,
      THEREFORE,
      for and
      in consideration of the mutual covenants and promises hereinafter contained,
      the
      parties hereto do intend to be legally bound hereby, do hereby agree as
      follows:

    

    ARTICLE
      1

    DEFINITIONS

    

    The
      following terms shall, for purposes of this Agreement, have the meanings
      designated to them under this Article unless otherwise specifically
      indicated.

    

    
      	1.1  	
              “Act”
                shall mean the Federal Food, Drug and Cosmetic Act, as amended, and
                regulations promulgated thereunder.

            

    

    

    
      	1.2  	
              “Affiliates”
                shall means with respect to a Party (a) corporation or business entity
                of
                which fifty percent (50%) or more of the securities or other ownership
                interests representing the equity, the voting stock, or general
                partnership interest are owned, controlled or held, directly or
                indirectly, by the Party; or (b) any corporation or business entity
                which,
                directly or indirectly, owns, controls or holds fifty percent (50%)
                or
                more of the securities or other ownership interests representing
                the
                equity, the voting stock or, if applicable, the general partnership
                interest, of the Party; or (c) any corporation or business entity
                of which
                fifty percent (50%) or more of the securities or other ownership
                interests
                representing the equity, the voting stock or general partnership
                interest
                are owned, controlled or held, directly or indirectly, by a corporation
                or
                business entity. 

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	1.3  	
              “Co-Promotion
                Date”
                is the date the TEAMM and Exaeris sales force begin detailing the
                Product.
                

            

    

    

    
      	1.4  	
              “Commercial Oversight
                Committee”
                shall be a committee consisting of one representative appointed by
                TEAMM
                and one representative appointed by Exaeris. The Oversight Marketing
                Committee shall perform the functions delegated to it
                herein.

            

    

    

    
      	1.5  	
              “Contract
                Year”
                shall mean a period of twelve (12) successive calendar months during
                the
                term of this Agreement; provided, however, the parties agree that
                the
                first Contract Year shall commence on the Launch Date and extend
                for 12
                consecutive months.

            

    

    

    
      	1.6  	
              “Detail”
                or “Detailing”
                shall mean, with respect to the Product, face-to-face activity undertaken
                by a Sales Representative during a sales call on licensed physicians
                to
                the “TEAMM Prescribers” or “Exaeris Prescribers” , in such physicians’
                offices or hospitals (excluding national conventions and other forms
                of
                communication not involving face-to-face contact by such sales
                representative), of describing the indicated uses, safety, effectiveness,
                contraindications, side effects, warnings and other relevant
                characteristics of the Product, in a fair and balanced manner consistent
                with the requirements of the Act, and when samples of the Product
                are
                provided to such licensed physicians, such action shall be evidenced
                by a
                sample form signed by the licensed physician, all in an effort to
                increase
                physician prescribing preferences of the Product for its indicated
                uses.

            

    

     

    
      	1.7  	
              “Exaeris
                Percentage”
                is that percentage calculated by taking the number of prescriptions
                that
                are credited to the Exaeris Prescribers divided by the total number
                of
                prescriptions written for the Product by both Exaeris Prescribers
                and
                TEAMM Prescribers in the same measurement period.
                

            

    

    

    
      	1.8  	
              “Exaeris
                Prescribers”
                shall mean those physicians that TEAMM and Exaeris have agreed will
                be
                Detailed by Exaeris Sales Representatives and will be used for determining
                Exaeris Percentage of prescriptions for purposes of compensation.
                

            

    

    

    
      	1.9  	
              “First
                Detailing Year”
                shall mean a period commencing on the Co-Promotion Date and ending
                approximately one year thereafter on the first day of the first full
                calendar month following the Co-Promotion Date. The Second through
                Last
                Detailing Years shall be successive one year periods which commence
                on the
                annual anniversary date of the first day of the first full calendar
                month
                following the Co-Promotion Date.

            

    

    

    
      	1.10  	
              “FDA”
                shall mean the United States Food and Drug Administration, or any
                successor entity thereto.

            

    

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    
      	1.11  	
              “Invoiced
                Sales”
                shall mean, * * * 

            

    

    

    
      	1.12  	
              “Launch”
                for purposes of this Agreement, shall mean the initial date that
                Product
                is shipped and invoiced to TEAMM’s customers.

            

    

    

    
      	1.13  	
              “Marketing
                Plan”
                shall mean for the Product, the marketing objectives, strategies
                and
                tactics and non-binding financial projections, including but not
                limited
                to, unit and dollar sales forecasts, advertising and promotion budgets,
                projections for sample quantities and cycle ship dates for such sample
                quantities, target audience and amendments from time to time thereto,
                developed and written by TEAMM.

            

    

    

    
      	1.14  	
              “Minimums”
                shall mean the minimum amount of measurements listed in Article 10.2
                (including but not limited to number of Sales Representatives, number
                of
                details, number of physicians detailed, percent of prescriptions
                generated) to meet contract obligations.

            

    

     

    
      	1.15  	
              “Net
                Quarter Sales”
                of Product or “Net Year Sales” shall be * *
                *.

            

    

    

    
      	1.16  	
              “Net
                Sales”
                shall mean the price charged by TEAMM for the Product in bona fide
                arm's
                length sales to unaffiliated parties in the United States after deduction
                of the following items: * * * 

            

    

    

    Such
      amounts shall be determined from TEAMM’s books and records which TEAMM shall
      maintain in accordance with generally accepted accounting principles (GAAP)
      consistently applied.

    

    
      	1.17  	
              “Net,
                Net Sales”
                shall mean * * * 

            

    

    

    
      	1.18  	
              “Person”
                shall mean a natural person, a corporation, a partnership, a limited
                liability company, a trust, a joint venture, any government authority
                or
                any other entity or organization. 

            

    

    

    
      	1.19  	
              “Prescriber
                Data”
                shall mean the Wolters Kluwer (previously known as NDC) Prescriber
                data
                publication compiled and published by Wolters Kluwer containing
                prescription data by prescribing
                physician.

            

    

    

    
      	1.20  	
              “Primary
                Detail”
                shall mean a detail on a product that is given as first product message
                and greatest emphasis in a sales
                call

            

    

    

    
      	1.21  	
              “Product”
                shall mean MD Turbo in finished package form marketed, distributed
                and
                sold by TEAMM as of the Effective Date

            

    

    

    
      	1.22  	
              “Product
                Contribution/Co-Promotion Payment”
                shall mean Net, Net Sales less a fixed distribution cost of *** and
                a
                fixed administrative cost of ***, both applied against invoiced sales.
                

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    
      	1.23  	
              “Product
                Development Agreement”
                shall mean the Product Development Agreement dated January 24, 2003
                and as
                amended, between TEAMM Pharmaceuticals, Inc. and Respirics, Inc.
                which
                provides for the license to TEAMM Pharmaceuticals to market MD Turbo.
                

            

    

    

    
      	1.24  	
              “Product
                Labeling”
                shall mean (a) the full prescribing information for the Product and
                (b)
                all labels and other written, printed or graphic matter upon any
                container, wrapper or any package insert or outsert with or for the
                Product.

            

    

    

    
      	1.25  	
              “Promote”,
                “Promotion”, “Promoting” or “Promotional”
                shall mean, with respect to the Product, those activities and obligations
                other than Detailing, to encourage sales of Product including but
                not
                limited to journal advertising, direct mail programs, convention
                exhibits
                and other forms of advertising and promotion specified in the Marketing
                Plan.

            

    

    

    
      	1.26  	
              “Product
                Promotional Materials”
                shall mean all sales representative training materials and all other
                printed, graphic, audio and video matter including but not limited
                to
                sales aids, study reprints, journal advertisements, direct mail and
                sales
                reminder aids (e.g.
                scratch
                pads, pens, and other such items) intended for use or used by
                representatives of either Exaeris or TEAMM in connection with Promotion
                or
                Detailing of the Product.

            

    

    

    
      	1.27  	
              “Quarter”
                shall mean a period of three (3) successive calendar months during
                the
                term of this Agreement. The first Contract Quarter shall commence
                upon the
                first day of the first quarter after the launch of the “product” (i.e.
                January, April, July or September). For purposes of this Agreement,
                should
                the Co-Promotion Date not fall on the first day of the quarter, the
                beginning period may include more than three months.
                

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        4

        
          

        

      

      
        
        

      

    

    

    
      	1.28  	
              “Quarter
                Sales” of Product shall
                mean the amount invoiced and recognized for the Products in the Territory
                during the respective period. For purposes of this agreement, product
                shipped in the last three days of a quarter are recognized in the
                following quarter. 

            

    

    

    
      	1.29  	
              “Respirics”
                (Respirics, Inc.)
                shall mean the developer and holder of the trademark(s) and patents
                for MD
                Turbo. 

            

    

    

    
      	1.30  	
              “Sales
                Representative(s)”
                shall mean an individual(s) in a sales function whose primary
                responsibility is to present the Product and who will be engaged
                in
                Detailing of the Product to health care professionals
                hereunder.

            

    

    

    
      	1.31  	
              “Sample(s)”
                or “Sampling Program”
                shall mean a MD Turbo or a MD Turbo Kit (includes a MD Turbo, mouth
                pieces
                and placebo inhaler) given to a healthcare professional for their
                use in
                demonstrating the device to patients.

            

    

    

    
      	1.32  	
              “Second
                Detail Position”
                shall mean a detail on a product that is given as second product
                message
                and consist of but not limited to, a full product detail on features,
                benefits and positioning statement.

            

    

    

    
      	1.33  	
              “Specifications”
                shall mean the specification for manufacturing and testing the Product
                as
                set forth in the approved 510(k)and any supplement or amendments
                thereto.
                

            

    

    

    
      	1.34  	
              “TEAMM
                Prescribers”
                shall mean those physicians detailed by TEAMM Sales Representatives
                as
                listed on Schedule A attached hereto and will be used for determining
                TEAMM Percentage of prescriptions. Schedule A may be updated from
                time to
                time by written notice from TEAMM to Exaeris.

            

    

    

    
      	1.35  	
              “Territory”
                shall mean the United States of America, its territories and possessions
                herein.

            

    

    

    
      	1.36  	
              “Trademarks”
                shall mean those trademarks and trade names, whether or not registered
                in
                the United States, trade dress and packaging which (a) are owned
                by either
                TEAMM or Respirics and are set forth in Exhibit 2 attached hereto
                and (b)
                are applied to or used with the Product or any Product Promotional
                materials.

            

    

      

    ARTICLE
      2

    APPOINTMENT

    

    
      	2.1  	
              TEAMM
                hereby enters into a non-exclusive co-promotion agreement and appoints
                Exaeris as its co-promotion marketing partner for the promotion of
                the
                Product in the United States and Exaeris hereby accepts such appointment
                to co-promote the Product in the United States in accordance with
                the
                terms and conditions hereof. Notwithstanding the foregoing, TEAMM
                shall
                retain the right to also promote the Product itself in the United
                States.
                

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    
      	2.2  	
              The
                Product will be sold only under TEAMM’s NDC number and therefore all sales
                will be recorded on TEAMM’s books and TEAMM will assume all responsibility
                for filing all reports required for each prescription NDC.
                

            

    

    

    
      	2.3  	
              Subject
                to the provisions of and during the term of this Agreement, Exaeris
                shall
                use reasonable commercial efforts consistent with accepted business
                practices and legal requirements to deploy its Sales Representatives
                to
                Detail the Product in the United States in such a manner and with
                such
                expedition as Exaeris itself would have adopted in Detailing a
                pharmaceutical product of its own taking into account the fact that
                TEAMM’s Sales Representatives will be Detailing and Promoting the Product
                in conjunction with Exaeris Sales Representatives and under the terms
                of
                this Agreement.

            

    

    

    
      	2.4  	
              TEAMM
                shall have the final authority on all prices and pricing strategies
                relating to the Product. TEAMM agrees to discuss with Exaeris, any
                proposed changes to pricing or pricing strategies prior to
                implementation.

            

    

    

    
      	2.5  	
              TEAMM
                reserves the right to enter into one or more co-promotion agreement(s)
                that would expand or supplement the geographic or prescriber base
                being
                Detailed on the Product, whether to include territories or prescribers
                not
                currently Detailed on the Product or to expand or intensify Detailing
                coverage. The planned addition of other co-promotion partners or
                expansion
                of territories will be discussed in advance with Exaeris to determine
                whether Exaeris has both the desire and the resources to assume
                responsibility for any expansion territory or expansion prescriber
                base
                other than that expansion by TEAMM’s sales force or TEAMM Prescriber List.
                In any event, the addition of any such expansion territory or prescriber
                base shall be by and in accordance with written agreement of TEAMM
                and
                Exaeris. 

            

    

     

    ARTICLE
      3

    SERVICES
      PROVIDED BY TEAMM

    

    
      	3.1  	
              TEAMM
                shall be responsible for all Product marketing and Product distribution,
                and shall carry out such responsibilities in accordance with the
                terms and
                conditions of this Agreement.

            

    

    

    
      	3.2  	
              TEAMM
                shall at its sole expense (except as otherwise expressly provided
                herein)
                have responsibility for performing the activities set forth below:
                

            

    

    

    
      	 	
              (a)

            	
              Contract
                for the manufacture of the Product and Samples, or arrange through
                Respirics for a third-party to contract manufacture the Product and
                Samples, in accordance with its established procedures in trade and
                Sample
                packs.

            

    

    

    
      	 	
              (b)

            	
              Maintain
                trade pack inventories of Product in accordance with inventory management
                systems TEAMM uses for other products of similar status and exposure
                in
                the marketplace.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        6

        
          

        

      

      
        
        

      

    

    
      	 	
              (c)

            	
              Communicate
                with the FDA in accordance with the Act for all Adverse Drug Experience
                Reports relating to Product. 

            

    

    

    
      	 	
              (d)

            	
              Distribute
                the Product pursuant to orders received from TEAMM’s wholesaler customers,
                its other direct customers or such other customers as may be mutually
                agreed upon by the parties hereto, in accordance with TEAMM’s normal
                business practices.

            

    

    

    
      	 	
              (e)

            	
              Invoice
                customers, collect payments, administer cash discounts for prompt
                payment
                and carry accounts receivable for the Product sold to TEAMM’s wholesaler
                customers, its other direct customers or such other customers as
                may be
                mutually agreed upon by the parties hereto, all in accordance with
                TEAMM’s
                normal business practices.

            

    

    

    
      	 	
              (f)

            	
              Process
                required payment of rebates to government or quasi-government agencies
                and
                hospital or other group purchasing
                organizations.

            

    

    

    
      	 	
              (g)

            	
              Prepare
                and submit to the Commercial Oversight Committee for its review all
                Marketing Plans and proposed appropriate marketing activities, expected
                to
                include agency management, convention management, marketing and sales
                promotion.

            

    

     

    
      	
            	
              (h)

            	
              Sales
                coverage and promotion to National Accounts (wholesalers and chains),
                Managed Care Organizations, and Federal and State Reimbursement
                plans.

            

    

    

    
      	3.3  	
              TEAMM
                shall provide financial information to Exaeris regarding sales as
                reported
                by the Prescriber Data and costs relating to the Product. This financial
                information will also include Invoiced Sales, wholesaler inventory
                levels,
                customer buying patterns and managed care formulary status.
                

            

    

    

    
      	3.4  	
              TEAMM
                will provide training assistance by making its sales trainer available
                to
                initial training at launch of Exaeris’ Sales Representatives at TEAMM’s
                expense. Exaeris will be responsible for all other training costs
                for
                their sales force (i.e.,
                meetings,
                travel, etc.). 

            

    

    

    
      	3.5  	
              TEAMM
                will provide Exaeris with developed Product Promotional Materials
                and
                Samples at quantities requested by Exaeris, at direct pass-through
                costs

            

    

    

    
      	3.6  	
              TEAMM
                will contract for and purchase, at its sole cost and expense, Prescriber
                Data as outlined in the agreement. 

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        7

        
          

        

      

      
        
        

      

    

    

    ARTICLE
      4

    SERVICES
      PROVIDED BY EXAERIS

    

    
      	4.1  	
              Exaeris
                will position the Product in no lower than a Second Position Detail
                to the
                Exaeris Prescribers, as documented by agreement of the parties and
                approved by TEAMM, throughout the term of the Agreement unless otherwise
                approved by both companies.

            

    

    

    
      	4.2  	
              Exaeris
                will provide updates of “Exaeris Prescribers” to TEAMM in an agreed upon
                format, with inclusion of necessary information (i.e. Medical Education
                (ME) number, etc) in an Excel spreadsheet as shown in Exhibit 3.
                TEAMM and
                Exaeris will share each others prescribers lists. Updates shall be
                sent by
                each Party to the other on a quarterly basis not later than 21 days
                in
                advance of the beginning of the quarter. TEAMM and Exaeris will review
                the
                Prescriber lists for a physician[s] that may appear on each company’s
                Prescriber lists and agree on which Prescriber list (or possibly
                both) the
                physician[s] will be credited.

            

    

    

    
      	4.3  	
              Exaeris
                will provide TEAMM with an annual forecast for Sample and Promotion
                Material requirements, which forecast shall be in accordance with
                the
                Marketing Plan and subject to review and approval by Commercial Oversight
                Committee. TEAMM will ship the samples to the location, compliant
                with
                PDMA guidelines, that Exaeris specifies at mutually agreed upon times
                at
                Exaeris costs.

            

    

    

    
      	4.4  	
              Exaeris
                will bear all sales force costs for Exaeris sales force including
                but not
                limited to salaries, expenses, benefits, company vehicles, and
                administrative costs. TEAMM will bear all sales force costs for TEAMM
                sales force including but not limited to salaries, expenses, benefits,
                company vehicles, and administrative
                costs.

            

    

    

    
      	4.5  	
              Exaeris
                will provide a bonus incentive on the product sales to the sales
                force
                customary to Exaeris’ current incentive plan and in line with the plan of
                action (POA). 

            

    

    

    
      	4.6  	
              Exaeris
                will have regularly scheduled POA and sales meetings to communicate
                promotional strategy for the respective time period with input from
                TEAMM
                as needed.

            

    

    

    
      	4.7  	
              In
                the unlikely event of a recall, Exaeris will cooperate with TEAMM
                to
                effect a cost-efficient recall to be compliant with any and all regulatory
                requirements and least disruptive to the business.
                

            

    

    

    
      	4.8  	
              Both
                during the term of this Agreement and after termination, each Party
                shall
                promptly notify the other of any Product complaint, including but
                not
                limited to any Adverse Drug Experience associated with the Product
                received by such Party. TEAMM shall investigate and handle all Adverse
                Drug Experiences associated with the Product, including those reported
                to
                TEAMM by Exaeris.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        8

        
          

        

      

      
        
        

      

    

     

    
      	4.9  	
              If
                Exaeris receives orders for the Product, Exaeris shall make all reasonable
                commercial efforts to forward such orders to TEAMM as soon as
                practicable.

            

    

    

    
      	4.10  	
              Exaeris
                shall allow for and support any marketing support programs including
                but
                not limited to “lunch and learn” programs, local and national conventions
                that would be compensatory to their spend on other Exaeris products
                and
                the product contribution.
                

            

    

    

    
      	4.11  	
              Exaeris
                will provide support of the Product at appropriate conventions and
                with
                Key Opinion Leader (KOL) development to the mutual benefit of Exaeris
                and
                TEAMM. This support will include providing Exaeris Sales Representative(s)
                to participate with TEAMM at TEAMM’s convention booths and/or to provide
                information and advertisements at Exaeris’ booth where appropriate and
                commensurate with the specialty importance Exaeris to assist TEAMM
                in KOL
                development to the extent mutually agreed upon.

            

    

    

    
      	4.12  	
              Exaeris’
                Representative will make the agreed upon number of pharmacy calls
                for
                purposes of pharmacy stocking and product availability as outlined
                in
                Article 10.2 .

            

    

     

    
      	4.13  	
              Exaeris
                will maintain their own call activity tracking system and provide
                periodic
                reports of call activity and Sample distribution to
                TEAMM

            

    

    

    
      	4.14  	
              Exaeris
                will contribute input to the Marketing Plan, strategy and marketing
                activities that are directed toward allergy and pulmonology
                specialists

            

    

    

    ARTICLE
      5

    MUTUAL
      COVENANTS

    

    
      	5.1  	
              Each
                Party shall cause its Sales Representatives to Detail the Product
                in the
                United States in accordance with the Marketing Plan developed by
                TEAMM and
                agreed upon by the Commercial Oversight Committee. Each Party will
                Promote
                the Product using the same professional sales and marketing standards
                as
                it uses for its own products.

            

    

    

    
      	5.2  	
              Each
                Party’s Sales Representatives shall make all Details in accordance with
                approved labeling. Sales Representatives shall distribute only the
                designated Promotional Materials with respect to Product pursuant
                to the
                Marketing Plan. In the performance of its obligations hereunder,
                each
                Party shall, and shall cause its Sales Representatives to, comply
                with all
                applicable laws and regulations, including without limitation the
                FDA and
                the regulations promulgated
                thereunder.

            

    

    

    
      	5.3  	
              Each
                Party will maintain and provide reports on sales calls, sample
                accountability, sample reporting, physician feedback and competitive
                information. Each Party will be responsible for submitting all necessary
                documentation to the appropriate agency to satisfy any state and
                federal
                regulations on sample accountability and reporting for their respective
                sales force and the samples shipped to it or their employees.
                

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        9

        
          

        

      

      
        
        

      

    

     

    
      	5.4  	
              Each
                Party will provide appropriate sales training (initial and ongoing)
                for
                their Sales Representatives necessary for Promotion of the Product
                and
                compliance with FDA regulations.

            

    

    

    
      	5.5  	
              Each
                Party will offer cooperation effort to coverage of Managed Care
                Organizations and Federal and State Reimbursement plans to the mutual
                benefit of both parties.

            

    

     

    ARTICLE
      6

    TRAINING

    

    
      	6.1  	
              During
                the term of this Agreement, Exaeris will conduct initial and ongoing
                training of this Product to their Sales Representatives. During the
                term
                of this Agreement, and at Exaeris’s option, TEAMM shall make available to
                Exaeris, upon a schedule to be arranged by discussion among the parties,
                to TEAMM sales training personnel who will assist Exaeris’ product and
                sales management teams in connection with the Detailing of the Product
                as
                outlined in Article 3.4. During the term of this Agreement, TEAMM
                shall
                also provide Exaeris, without cost to Exaeris, with reasonable quantities
                of training materials for the Product which have been created and
                developed by TEAMM. Exaeris shall have the responsibility for, and
                control
                over, the manner in which it trains its Sales Representatives with
                respect
                to the Product, however the training shall be consistent with the
                Marketing Strategies and compliant with FDA
                regulations.

            

    

     

    ARTICLE
      7

    COORDINATION

    

    
      	7.1  	
              The
                parties shall each appoint an authorized representative (“Coordinator”)
                who shall have principle responsibility for inter-company communications
                relating to the Product and to whom notices and correspondence relating
                to
                this Agreement will be directed. Each party will notify the other
                as to
                the name of the individual so appointed. Each party may replace its
                Coordinator at any time, upon written notice to the other
                party.

            

    

    

    
      	7.2  	
              The
                Coordinators shall establish a Commercial Oversight Committee (Committee)
                within thirty (30) days following signing of the Agreement. This
                Committee
                will be directed by the Coordinators and consist of representatives
                of
                each party who will meet within sixty (60) days of the Effective
                Date of
                this Agreement to develop a co-promotion launch plan and thereafter
                from
                time to time, at mutually agreeable times and locations to discuss
                and
                coordinate the joint Detailing of the Product in the United States
                and the
                strategies and programs that should be developed to maximize the
                sales of
                the Product. Illustratively, the Committee shall (i) coordinate Exaeris’
                launch of the Product in the United States and (ii) guide all continuing
                joint detailing efforts with respect to the Product in the United
                States.
                TEAMM will have the final authority and responsibility, with the
                cooperation and assistance of Exaeris, for developing detailing and
                promotion strategies with respect to the
                Product.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        10

        
          

        

      

      
        
        

      

    

     

    
      	7.3  	
              Exaeris
                physician targets and call plans shall be agreed upon by Exaeris
                and TEAMM
                and will be the subject of the Exaeris Prescriber List on which
                compensation will be based. TEAMM and Exaeris will exchange and compare
                each party’s Prescriber List and Exaeris will make reasonable efforts to
                call on high prescribing specialists (allergists, pulmonologists,
                pediatricians and primary care) included in their geographic area
                and not
                called on by TEAMM’s Sales
                Representatives.

            

    

    

    
      	7.4  	
              From
                time to time, but in no event less than once a year, the Commercial
                Oversight Committee shall develop and formulate joint Marketing Plans
                for
                specified periods (collectively, the “Marketing Plan” ) which shall set
                forth detailing, promotion, sampling and marketing strategies for
                each
                party relating to the Product. The provisions of the Marketing Plan
                shall
                be agreed to by the Coordinators, and if the Coordinators cannot
                agree,
                then the matters in dispute shall be referred to the Chief Operating
                Officers of the parties. TEAMM, however, shall have the final
                responsibility for, and control over, the development and content
                of the
                Marketing Plan. Unless otherwise agreed to by the parties, the initial
                representatives from Exaeris and TEAMM will be * * * . Replacements
                for
                such individuals shall be of no less seniority than Director of Marketing.
                The Committee, at it’s discretion, can include additional members from the
                companies provided each company has equal representation.
                

            

    

    

    
      	7.5  	
              Each
                party shall bear its own costs associated with its participation
                in the
                Committee.

            

    

    

    
      	7.6  	
              At
                all times, Detailing, Promotional and Sampling activities will be
                consistent with the requirements of federal
                regulations.

            

    

    

    
      	7.7  	
              During
                the term of and subject to any other provision of this Agreement,
                each
                party will provide the other with all information relevant to the
                detailing and promotion of the Product within a reasonable time after
                such
                information becomes known to the party, provided such information
                is not
                received under a secrecy obligation or is otherwise confidential
                or
                proprietary.

            

    

    

    
      	7.8  	
              On
                a quarterly basis the Commercial Oversight Committee (Committee)
                shall
                provide to the parties a written report on the activities and performance
                of the co-promotion effort. The content and structure and presentation
                format of this report will be determined by the Committee, however,
                at a
                minimum, the report will contain year to date sales performance,
                variance
                to budget, detailing activity, promotional spend vs. budget and a
                TEAMM
                prescription analysis on the following subsets of physicians: jointly
                detailed physicians; TEAMM only and Exaeris
                only.

            

    

    

    
      	7.9  	
              Exaeris
                agrees to Promote the Product in accordance with the provisions set
                forth
                in this Agreement and to follow the marketing strategies as outlined
                in
                the Marketing Plan, as it may be amended and supplemented by the
                Committee
                during the Term of this Agreement. 

            

    

    

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        11

        
          

        

      

      
        
        

      

    

    

    ARTICLE
      8

    PROMOTIONAL
      MATERIALS

    

    
      	8.1  	
              During
                the term of this Agreement, TEAMM shall create and develop, with
                the
                assistance and cooperation of Exaeris, sales and Promotional Materials
                relating to the Product for distribution to independent third parties.
                TEAMM shall provide Exaeris with such materials, in amounts which
                are
                reasonable under the terms of the Marketing Plan. Other than with
                the
                advice and written consent of TEAMM, Exaeris shall not create or
                develop
                sales, promotional or other similar material relating to the Product
                for
                distribution to independent third parties, including members of the
                medical and health professions. Exaeris shall reimburse TEAMM for
                the
                costs incurred by TEAMM to produce such all such sales and Promotional
                Material supplied to Exaeris relating to the Product. The costs to
                Exaeris
                will be the direct pass through costs incurred by TEAMM for the printing
                and shipping of sales and Promotional Materials in quantities requested
                by
                Exaeris. Exaeris will be responsible for agency costs only for material
                that have been requested by Exaeris and for their sole use.
                

            

    

    

    
      	8.2  	
              Exaeris
                shall provide TEAMM with a list of Promotional Materials it agrees
                to
                utilize in the promotion of the Product and a schedule setting forth
                Exaeris’ request for such materials and their delivery dates, all of which
                shall be reasonable under then existing marketing conditions and
                subject
                to approval by TEAMM. TEAMM shall promptly inform Exaeris whether
                it can
                deliver such materials in accordance with such schedule. If TEAMM
                cannot
                meet the delivery schedule, Exaeris, at its option, shall have the
                right
                to have prepared, at its own expense, additional supplies of such
                material, provided that such additional supplies conform in all respects
                with the material produced by TEAMM. If requested by Exaeris, TEAMM
                shall
                use its best efforts to provide Exaeris, free of charge, with mechanical
                and other items necessary to prepare such additional
                supplies.

            

    

    

    
      	8.3  	
              Exaeris
                shall not be required to distribute any sales and Promotional Material
                prepared after the date of this Agreement which (i) does not mention
                the
                Product, or (ii) includes a reference to another TEAMM pharmaceutical
                product in addition to the Product. In no event shall TEAMM be required
                to
                distribute any material which contains a reference (i) to Exaeris
                (other
                than in connection with the Detailing of the Product in accordance
                with
                this Agreement) or (ii) any Exaeris pharmaceutical. Exaeris is not
                obligated to utilize all Promotional Materials developed by
                TEAMM.

            

    

    

    
      	8.4  	
              TEAMM
                and Exaeris shall comply with the terms of this Agreement and all
                applicable laws and regulations, including, without limitation, the
                FDA
                and the regulations promulgated thereunder with respect to the sales
                and
                Promotional Materials described
                herein.

            

    

    

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        12

        
          

        

      

      
        
        

      

    

    ARTICLE
      9

    SAMPLING

    

    
      	9.1  	
              To
                achieve the objectives of this Agreement, both parties recognize
                that it
                is necessary to distribute the Product * * * as Samples to health
                care
                professionals on an ongoing basis (“Sampling Program”) and in a manner
                consistent with the Marketing Plan. For any such Sampling Program,
                the
                Coordinators, from time to time, shall establish a reasonable sampling
                strategy, setting forth a sampling period, the number of Samples
                to be
                distributed during such sampling period and the delivery schedule
                for
                Samples. TEAMM shall provide Exaeris with all of Exaeris’ reasonable
                requirements for Samples of the Product as allotted under any such
                Sampling Program. Exaeris shall reimburse TEAMM for the costs incurred
                by
                TEAMM to provide such Samples. TEAMM shall ship Exaeris’s requirements of
                samples to such Exaeris facilities as Exaeris may designate. Samples
                shall
                be allotted on a per capita basis to the Exaeris sales force and
                the TEAMM
                sales force as modified by the expected amount of time and effort
                to be
                used by each sales force in Detailing the Product to each class of
                account
                and by the Sampling Program. All samples delivered to Exaeris shall
                be
                packaged in the same form and be of the same quality as Samples of
                the
                Product which TEAMM normally distributes to health care professionals
                or
                to the trade in the United States. TEAMM shall be allowed, for good
                cause,
                to require Exaeris to make an accounting for all samples by so notifying
                Exaeris in writing.

            

    

    

    
      	9.2  	
              Each
                party shall comply with all laws and regulations applicable to the
                distribution of Samples of the Product, including without limitation,
                the
                Prescription Drug Marketing Act of 1987 (“PDMA”). The parties shall keep
                all records and reports required to be kept by applicable laws and
                regulations and make its facilities available at reasonable times
                during
                business hours for inspection by the other party and representatives
                of
                governmental agencies. Each party shall promptly provide to the other
                party a copy of all correspondence with FDA related to PDMA
                compliance.

            

    

     

    ARTICLE
      10

    SALES
      COVERAGE

    

    
      	10.1  	
              Exaeris
                will call on * * * as defined in Exaeris’ Prescriber List, as well as
                pharmacy and third party reimbursement customers. As Exaeris wishes
                to add
                new sales territories, Exaeris will inform TEAMM of this intention
                in
                writing and shall work with TEAMM to add these territories in a manner
                which does not conflict with TEAMM’s coverage at that time, subject always
                to TEAMM’s discretion in permitting this intended expansion by Exaeris.
                TEAMM will be given first right to call on any physician that appears
                on
                both TEAMM and Exaeris current Prescriber List or expansion list.
                Both
                parties will collaborate to complement each other’s future sales coverage
                territories on a best efforts basis. Exaeris and TEAMM will apprise
                each
                other of their respective sales territory expansion plans in respect
                to
                the Promotion of Product as they become known and as far in advance
                as is
                feasible so that these new territories can be accommodated to the
                extent
                commercially reasonable. Exaeris will provide TEAMM with a list of
                prescribers in the required format ( as outlined in Exhibit 3) to
                track
                prescriptions through Prescriber Data source. New Prescribers may
                be added
                on a quarterly basis in a time frame mutually agreed upon in advance
                of
                the Quarter but not to be less than three (3) weeks in advance of
                the
                first day of the new Quarter, subject to acceptance and approval
                by TEAMM.
                TEAMM and Exaeris will exchange and compare each party’s Prescriber List
                and Exaeris will make reasonable efforts to call on high prescribing
                specialists (allergists, pulmonologists, pediatricians and primary
                care)
                included in their geographic area and not called on by TEAMM’s Sales
                Representatives.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        13

        
          

        

      

      
        
        

      

    

     

    It
      is
      hereby expressly understood and agreed by and between TEAMM and Exaeris that
      TEAMM shall at all times have the right to call on any and all prescribers,
      either through its own Sales Representatives or through one or more co-promotion
      arrangements, other than Exaeris’ Prescribers as that list may exist and be
      updated from time to time through the Term of this Agreement.

    

    
      	10.2  	
              Minimums:

            

    

    

    
      	a.  	
              Exaeris
                commits to having a minimum of ***
                Detailing Sales Representatives hired and prepared to Promote as
                of the
                date of Launch with physician coverage of an average of *** target
                physicians per Representative

            

    

    

    
      	b.  	
              Exaeris’
                physician coverage shall consist of a minimum of *** physicians with
                a
                target of *** allergists, *** pulmonologists, *** pediatricians and
                ***
                primary care physicians. Further, Exaeris commits to a minimum of
                ***
                physician Details in calendar year 2006 and *** physician details
                in
                calendar year 2007 and *** physician details for the period January-March
                of 2008 

            

    

    

    
      	c.  	
              Additionally,
                Exaeris shall cause its Sales Representatives to make a minimum of
                ***
                pharmacy calls in the first *** months of launch in 2006 and ***
                pharmacies calls per week per representative thereafter.
                

            

    

    

    
      	d.  	
              Product
                shall be in no less than a *** Detail Position throughout the term
                of this
                Agreement.

            

    

    

    
      	e.  	
              Exaeris’
                percent of prescriptions as reported by “Prescriber Data” shall not fall
                below ***. For purposes of this agreement, the number of Sales
                Representatives shall include the count of open territories. This
                minimum
                requirement is waived for the first *** reporting period (quarter)
                following the launch date.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        14

        
          

        

      

      
        
        

      

    

     

    
      	10.3  	
              Activity
                Audits.
                No later than sixty (60) days after the conclusion of each Quarter,
                Each
                party will provide a report, based upon internal Detailing report
                data
                setting forth Details for the Products for the preceding Quarter
                including
                acknowledgments of Samples distributed for such quarter. In addition,
                Exaeris agrees to make available to TEAMM, upon reasonable advance
                notice,
                such other books and records necessary to verify the accuracy of
                such
                report in respect of any Quarter ending not more than eighteen (18)
                months
                prior to the date of such request. Upon expiration of eighteen (18)
                months
                following the end of any Quarter, unless prior to such expiration,
                based
                upon such inspection, TEAMM has notified Exaeris of an issue regarding
                such report, the report reflecting Exaeris Product Details for such
                Quarter shall be binding; and Exaeris shall be released from any
                liability
                or accountability to TEAMM with respect to the number of Product
                Details
                given during such Quarter.

            

    

     

    ARTICLE
      11

    COMPENSATION

    

    
      	11.1  	
              TEAMM
                shall pay Exaeris a Co-Promotion Payment based on Exaeris’ Percentage of
                *** credited to the Exaeris’ Prescribers based on the terms as outlined
                below. An example of the calculations in this article is provided
                in ***.
                

            

    

    

    
      	a.  	
              For
                Invoiced sales of Product, Exaeris’ Co-Promotion Payment shall be based on
                Exaeris’ Percentage of prescriptions generated by Exaeris’ Prescribers as
                reported by Prescriber Data and determined by the calculation outlined
                in
                Article 11.1(b) applied against unit Invoiced Sales for the reporting
                quarter at the Product Contribution-Co-Promotion payment per unit
                outlined
                in Article 11.1 (e)

            

    

    
      	b.  	 

    

    

    ***

    

    
      	c.  	
              Should
                TEAMM and Exaeris mutually agree to dual coverage on a physician,
                Exaeris
                share of *** for dual coverage physician(s) will be *** of the ***
                by such
                physician(s).

            

    

    

    
      	d.  	
              Exaeris’
                Percentage of *** shall be calculated as an average over a Quarter.
                However, the first period in which this percentage is averaged may
                include
                more than three months. For this period only, the *** will be averaged
                over the longer period to adjust for stocking, however, the first
                co-promotion payment will be made after the first full Quarter in
                an
                effort to provide a fair average of *** activity to be applied against
                the
                initial stocking of the Product. For example, if Quarter Sales begin
                March 27, 2006 and Detailing begins May 1, 2006, the first full
                Quarter would conclude at the end of September. In this example Exaeris
                would receive a co-promotion payment after the completion of the
                first
                full quarter in the time frame outlined in this Agreement in 11.3.,
                However, the co-promotion payment at the end of September would be
                based
                on a computation of Exaeris’ Percentage of *** over the period beginning
                May 1st
                through September 30th.
                This percentage will be applied against Quarter Sales from March
                27th
                and
                including Quarter Sales through the Quarter ending September 2006.
                However
                a payment of *** will be made to Exaeris for the first partial quarter
                for
                their efforts during training, launch and initial detailing period
                and
                paid six weeks after June 30, 2006. This payment will be credited
                against
                the total amount due Exaeris for the period from the Launch of the
                Product
                to the end of the first full quarter during which the product has
                been
                Detailed. 

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        15

        
          

        

      

      
        
        

      

    

     

    
      	e.  	
              Compensation
                would be based on the following formula (example in Exhibit
                1)

            

    

    

    ***

     

    
      	11.2  	
              All
                accruals for the first twelve months will be calculated using the
                estimated percentages stated in 11.1(e). A reconciliation to actual
                deductions will be calculated no later than 90 days following the
                first
                twelve months after Detailing begins. The actual percentages will
                be the
                basis for the estimated accruals from that point until the next
                reconciliation.

            

    

    

    
      	11.3  	
              Unless
                otherwise indicated in this Section, TEAMM shall pay to Exaeris,
                within
                *** weeks of the close of each calendar Quarter in a Detailing Year,
                a
                Co-Promotion Payment equal to:

            

    

    

    
      	a.  	
              The
                Co-Promotion Payment payable to Exaeris for the Detailing Quarter
                (calculated through the end of such calendar quarter) calculated
                in
                accordance with 11.1. 

            

    

    

    
      	b.  	
              Within
                *** days after the close of each calendar quarter, TEAMM shall submit
                to
                Exaeris a reconciliation report outlining the calculation of the
                payments
                made to Exaeris. 

            

    

    

    
      	11.4  	
              Exaeris
                agrees to compensate TEAMM for its prior development, marketing and
                inventory carrying costs by development compensation payments totaling
                ***
                to be paid as indicated below:

            

    

    

    ***

    

    
      	11.5  	
              The
                amount of each payment due to Exaeris pursuant to this article shall
                be
                adjusted by deducting all outstanding and unpaid TEAMM invoices presented
                to Exaeris for development compensation payments, Samples and Product
                Promotional Materials due to TEAMM under this Agreement during the
                period
                for which payment is calculated. In the event that such invoices
                are in
                excess of the amount due to Exaeris for such period, Exaeris shall
                pay the
                amount of such excess to TEAMM.

            

    

    

    
      	11.6  	
              The
                parties hereto expressly understand and agree that TEAMM shall be
                entitled
                to rely solely on the Prescriber Data to calculate Exaeris’ Percentage
                used in calculating the Co-Promotion Payments due
                Exaeris.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        16

        
          

        

      

      
        
        

      

    

     

    
      	11.7  	
              TEAMM
                shall keep adequate records to account for the sums due to Exaeris
                under
                this Agreement. Such records shall be retained by TEAMM and shall
                be made
                available for reasonable review and audit, at the request and expense
                of
                Exaeris, by an independent certified public accountant appointed
                by
                Exaeris and reasonably acceptable to TEAMM for the purposes of verifying
                TEAMM’s accounting reports hereunder. The documents from which the
                accounting required by this Article have been prepared shall be retained
                for the lesser of one (1) year after the completion of an audit thereof,
                if an audit has been requested, or three (3) years from the date
                of the
                documents originate.

            

    

    

    
      	11.8  	
              All
                sums due to Exaeris shall be payable in U.S. dollars by TEAMM on
                the
                specified due date at the address set forth in Article
                20.2.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        17

        
          

        

      

      
        
        

      

    

     

    ARTICLE
      12

    CONFIDENTIALITY

    

    
      	12.1  	
              The
                provisions of the Confidentiality and Non- Disclosure Agreement relating
                to the non-disclosure and non-use of Proprietary Information belonging
                to
                either party, entered into previously by the parties, shall apply
                to any
                such information disclosed by either party to the other party in
                connection with this Agreement, and the terms of that Confidentiality
                and
                Non- Disclosure Agreement, dated as of November 14, 2005 and signed
                November 22, 2005, are hereby incorporated herein and made a part
                hereof.
                Any breach thereof shall be deemed to be a breach of this Agreement.
                

            

    

     

    ARTICLE
      13

    PUBLICITY/PRESS
      RELEASES

    

    
      	13.1  	
              Neither
                party shall distribute or have distributed any such information which
                bears the name of the other without the prior written approval of
                the
                other, which approval shall not be unreasonably withheld. The Product
                shall be represented solely as a TEAMM product. When packaged, the
                Product
                will bear the TEAMM name (as distributor) and the manufacturer’s name
                only. All promotional and sales materials, not currently printed,
                that are
                intended for use by both parties in the Promotion of the Product
                will
                include the identity of both parties and will represent Exaeris as
                a
                co-promotion partner or as providing marketing support.
                

            

    

    

    
      	13.2  	
              The
                parties agree to issue a joint press release announcing the co-promotion;
                provided that no publicity release or announcement concerning this
                Agreement or the transactions contemplated hereby shall be issued
                without
                the advance written consent of the other, such consent not to be
                unreasonably withheld, except as such release or announcement may
                be
                required by law, in which case the party making the release or
                announcement shall, before making any such release or announcement,
                afford
                the other party a reasonable opportunity to review and comment upon
                such
                release or announcement. TEAMM and Exaeris recognize that disclosure
                of
                this Agreement (including copies of each) to the I.R.S.(Internal
                revenue
                Service), SEC (Security Exchange Commission) and other governmental
                authorities may be required, and each waives the requirements of
                this
                subsection with respect to disclosure (and copies) to such
                entities.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        18

        
          

        

      

      
        
        

      

    

     

    ARTICLE
      14

    TERM
      AND TERMINATION

    

    
      	14.1  	
              The
                initial term of this Agreement shall commence on the Effective Date
                and
                shall continue for a period of twenty-four (24) consecutive months,
                unless
                earlier terminated in accordance with the provisions of thisArticle
                14.
                This Agreement is renewable for subsequent twelve (12) month periods
                thereafter only by written agreement signed by both parties.
                

            

    

    

    
      	14.2  	
              Notwithstanding
                any other provision of this Agreement, either party may terminate
                this
                Agreement by notice in writing to the other upon or at any time after
                the
                occurrence of any of the following
                events:

            

    

    

    
      	a.  	
              If
                the other commits a material breach of this Agreement, or fails to
                perform
                any material obligation under this Agreement, which (i) shall not
                have
                been remedied within ninety (90) days of the receipt by the other
                of a
                notice identifying the breach and (ii) continues to exist at the
                time of
                notice of termination; or Exaeris is unable to meet the minimum
                requirements outlined in this agreement.

            

    

    

    
      	b.  	
              If
                the other is unable to pay its debts, becomes bankrupt or insolvent,
                or
                enters into liquidation whether compulsorily or voluntarily or compounds
                with or convenes a meeting of its creditors or has a receiver appointed
                over all or part of its assets or takes or suffers any similar action
                in
                consequence of a debt or ceases for any reason to carry on
                business.

            

    

    

    
      	14.3  	
              Notwithstanding
                any other provision herein to the contrary, either party may terminate
                this Agreement at any time for any reason by giving the other party
                ninety
                (90) days prior written notice of such termination, specifying the
                effective date of such termination. Termination by Exaeris under
                this
                Article shall not release TEAMM from any obligation to pay Exaeris
                any
                sums due or accrued under this Agreement through the effective date
                of
                termination or release Exaeris from any obligation to pay TEAMM any
                sums
                due under this agreement. This payment obligation shall include,
                without
                limitation, the reconciliation of accrued discounts and rebate to
                actual
                amount incurred. In addition, should Exaeris terminate this agreement
                without cause before all outstanding development compensation payments
                are
                received by TEAMM or TEAMM terminates due to Exaeris’ material breach,
                Exaeris agrees to make immediate payment to TEAMM of the remaining
                outstanding development compensation payments in recognition of the
                credit
                for stocking paid to Exaeris. If TEAMM terminates for any reason
                other
                than material breach by Exaeris, then Exaeris shall have no further
                obligation to make any development payments which accrued subsequent to
                the termination date. 

            

    

    

    
      	14.4  	
              The
                expiration or termination of this Agreement shall not relieve the
                parties
                hereto of any liability which accrued hereunder prior to the effective
                date of such expiration or termination nor preclude either party
                from
                pursuing all rights and remedies it may have hereunder or at law
                or in
                equity with respect to any breach of this Agreement nor prejudice
                either
                party’s right to obtain performance of any obligation provided for in this
                Agreement which expressly survives termination or
                expiration.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        19

        
          

        

      

      
        
        

      

    

     

    
      	14.5  	
              Any
                dispute that may arise under this Agreement shall first be submitted
                to
                Mediation through the Commercial Oversight Committee created pursuant
                to
                Article 7 herein, and/or by mediators selected and appointed by the
                Committee. If the Parties fail to resolve a dispute through mediation
                within thirty (30) days of the request to mediate, and a party wishes
                to
                pursue the matter, each such dispute, controversy, that is not considered
                an “Excluded Claim” shall be finally resolved by binding arbitration in
                accordance with the Commercial Arbitration Rules of the American
                Arbitration Association (“AAA”) with Supplementary Procedures for
                Commercial Arbitration, and Supplementary Procedures for Large Complex
                Cases. Judgment on the arbitration award may be entered in any court
                having jurisdiction thereof. The arbitration shall be conducted by
                a panel
                of three (3) persons experienced in the pharmaceutical business:
                within
                thirty (30) days after initiation of arbitration, each party shall
                select
                one (1) Person to act as arbitrator and the two-party selected arbitrators
                shall select a third arbitrator within thirty (30) days of their
                appointment. If the arbitrators selected by the parties are unable
                or fail
                to agree upon the third arbitrator, the AAA shall appoint the third
                arbitrator. The place of arbitration shall be Raleigh, North Carolina.
                Either party may apply to the arbitrators for interim injunctive
                relief
                until arbitration award is rendered or the controversy is otherwise
                resolved. Either party also may, without waiving any remedy under
                this
                Agreement, seek from any court having jurisdiction any injunctive
                or
                provisional relief necessary to protect the rights or property of
                that
                party pending the arbitration award. The arbitrators shall have no
                authority to award punitive, special, consequential, or any other
                type of
                damages not measured by a party’s compensatory damages. Each party shall
                bear its own costs and expenses and attorneys’ fees, and an equal share of
                the arbitrators’ and any administrative fees of arbitration. Except to the
                extent necessary to confirm an award or as maybe required by law,
                neither
                a party nor an arbitrator may disclose the existence, content, or
                results
                of arbitration without the prior written consent of both parties.
                In no
                event shall arbitration be initiated after the date a legal or equitable
                proceeding based on the dispute, controversy or claim would be barred
                by
                the applicable North Carolina statute of limitations. As used in
                this
                Section, the term “Excluded Claim” shall mean a dispute, controversy or
                claim that concerns (i) the validity or infringement of a patent,
                trademark or copyright; or (ii) any antitrust, anti-monopoly or
                competition law or regulations, whether or not
                statutory.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        20

        
          

        

      

      
        
        

      

    

    

      	14.6  	
              Recognizing
                that immediate and irreparable injury may result to the non-breaching
                party (“Non-Breaching Party”), it’s business and property in the event of
                a continuing breach of any of the provisions of Articles 3, 4, 5
                and 10.2
                by a party, that such provisions are necessarily of a special, unique
                and
                extraordinary nature and that any loss arising from a breach of any
                such
                provision may not reasonably and adequately be compensated by monetary
                damages, and because this Agreement is based in significant measure
                upon
                such provisions, the party breaching any of the covenants of Articles
                3,
                4, 5 and 10.2 as applicable (“Breaching Party”), expressly agrees that in
                the event of a violation of such provisions, the Non-Breaching Party
                shall
                be entitled, in addition to any other remedies and damages the
                Non-Breaching Party could recover as a result of any such violation,
                to
                seek restraining orders and/or injunctions, both temporary and permanent,
                in order to prevent any future violations -thereof
                by the Breaching Party. Any bond required to be posted by the
                Non-Breaching Party with regarding to the enforcement of this Section
                shall be limited to ***. 

            

    

     

    
      	14.7  	
              Consequences
                of Termination.

            

    

    

    
      	a.  	
              In
                the event of termination of this Agreement under Article 14 hereof,
                any
                payments payable pursuant to Article 11 hereof shall be made only
                with
                respect to the Quarterly Sales generated prior to the effective date
                of
                such termination.

            

    

    

    
      	b.  	
              Except
                as set forth herein, any termination, cancellation or expiration
                of this
                Agreement shall not relieve either party of any obligation which
                has
                accrued prior to the date of such termination, cancellation or expiration,
                including but not limited to, such party’s obligations under Article 11 of
                this Agreement, which obligation shall remain in full force and effect
                for
                the period provided therein or if no period is provided,
                indefinitely.

            

    

    

    
      	c.  	
              In
                the event of termination of this Agreement by Exaeris during first
                six
                months, except for cause due to material breach by TEAMM, Quarterly
                Sales
                will be adjusted to reflect more accurately the payment on sales
                created
                through prescriptions for that period rather than Product stocking
                in
                wholesalers and retail accounts. In this situation, the co-promotion
                payment due to Exaeris would be calculated on prescriptions written
                by
                Exaeris Prescribers as reported through Prescriber
                Data.

            

    

    

    
      	d.  	
              Termination
                of this Agreement does not relieve Exaeris from development compensation
                payments agreed to and due to TEAMM. Notwithstanding the foregoing,
                in the
                unlikely event that the Product is not available for commercial
                distribution for a period of six (6) months or greater subsequent
                to the
                Launch Date, Exaeris shall not responsible for any outstanding Development
                compensation as due in Article 11.4 until such time as the Product
                is once
                again available for commercial
                distribution.

            

    

    

    
      	14.8  	
              Returned
                Materials.
                Upon the termination of this Agreement, TEAMM and Exaeris each shall
                return to the other all information which it possesses or controls
                that
                belongs to the other, except that each may retain a copy for recordkeeping
                purposes

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        21

        
          

        

      

      
        
        

      

    

     

    ARTICLE
      15

    NON-COMPETE

    

    
      	15.1  	
              Exaeris
                agrees that during the Term of the Definitive Agreement and for one
                (1)
                year post-termination of the Agreement other than for breach by TEAMM
                or
                termination by TEAMM without cause, Exaeris and its affiliates will
                not
                develop, produce, market or sell or cause to be developed, produced,
                marketed or sold any after market products that is or is designed
                to
                convert a metered dose inhaler (MDI) into a breath-activated delivery
                with
                dose counter which would compete directly with the Product (other
                than the
                Product) (“Competing Product”). TEAMM agrees during the term of the
                Definitive Agreement, it will not develop, produce, market or sell
                or
                cause to be developed, produced, marketed or sold any Competing
                Product.

            

    

    

    ARTICLE
      16

    TRADEMARK

    

    
      	16.1  	
              Exaeris
                shall Promote and Detail the Product only under the
                Trademark(s).

            

    

    

    
      	16.2  	
              Each
                party acknowledges the validity of the other party’s right, title and
                interest in and to its or it’s partners Trademark(s) and shall not have,
                assert or acquire any right, title or interest in or to any such
                other
                party’s Trademark(s).

            

    

    

    
      	16.3  	
              Exaeris
                shall use the product Trademark(s) only in the manner provided for
                in
                hereof or as otherwise directed by TEAMM and shall not use any Trademark
                on any other goods or Products notwithstanding that such goods or
                Products
                are dissimilar to the Product or have a different
                use.

            

    

     

    ARTICLE
      17

    INSURANCE

    

    
      	17.1  	
              TEAMM
                shall at all times maintain insurance, including but not limited
                to
                product liability insurance, in commercially reasonable amounts for
                its
                respective obligations and potential liabilities in an amount no
                less than
                ***
                million dollars (***) per occurrence and in the aggregate.
                TEAMM will name Exaeris as additionally insured under its product
                liability policy. Exaeris shall at all times maintain general liability,
                workman’s compensation, auto and professional liability insurance, in
                commercially reasonable amounts for its respective obligations and
                potential liabilities in an amount no less than ***
                million dollars (***)
                per occurrence and in the aggregate. Exaeris will name TEAMM as
                additionally insured under its general liability, auto and professional
                liability policies. Each party shall, at the request of the other
                party,
                provide such evidence of such insurance as requested, including a
                certificate of insurance.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        22

        
          

        

      

      
        
        

      

    

     

    ARTICLE
      18

    INDEMNIFICATION

    

    
      	18.1  	
              (a)
                Each party hereto (the “Indemnifying Party”) shall indemnify, defend and
                hold harmless the other party hereto, its directors, officers, employees
                and Affiliates (collectively, the “Indemnified Parties”) from and against
                any and all Damages incurred or suffered by the Indemnified Parties
                to the
                extent arising out of any breach of this Agreement by the Indemnifying
                Party or out of the sole or contributory negligence of the Indemnifying
                Party in performing its obligations under this
                Agreement.

            

    

    

    (b)
      Exaeris agrees to indemnify, defend and hold harmless the TEAMM Indemnified
      Parties against any claim, action, suit or proceeding, settlement amounts or
      damages, liabilities, costs and expenses (including reasonable attorneys' fees)
      (“Claim”) by a third party alleging that any materials provided by Exaeris
      (other than those received from TEAMM) infringes or violates any intellectual
      property rights of such third party. 

    

    (c)
      TEAMM
      agrees to indemnify, defend and hold harmless the Exaeris Indemnified Parties
      against any Claim by a third party (i) alleging that any materials provided
      by
      TEAMM (other than those received from Exaeris) infringes or violates any
      intellectual property rights of such third party or (ii) arising out of the
      use
      of Product whether under product liability or otherwise. 

    

    
      	18.2  	
              Any
                Indemnified Party shall notify the Indemnifying Parties of any potential
                claim , and both parties agree that the indemnification provisions
                set
                forth in this agreement thereof shall apply to and govern any claims
                for
                indemnification under this
                Agreement.

            

    

    

    
      	18.3  	
              This
                Section shall survive the expiration or termination of this
                Agreement.

            

    

     

    ARTICLE
      19

    REPRESENTATION
      AND WARRANTIES

    

    
      	19.1  	
              Exaeris
                is a corporation duly organized and validly existing under the laws
                of the
                State of Delaware. Exaeris has all necessary corporate power and
                authority
                to enter into, and be bound by the terms and conditions of this agreement.
                

            

    

    

    
      	19.2  	
              The
                execution, delivery and performance by Exaeris of this Agreement
                and each
                agreement of instrument contemplated by this Agreement and the performance
                of the transactions contemplated hereby and thereby, have been duly
                authorized by all necessary corporate action by Exaeris. This Agreement
                is, and each agreement or instrument contemplated by this Agreement,
                when
                executed and delivered by Exaeris in accordance with the provisions
                hereof, will be the legal, valid and binding obligation of Exaeris,
                in
                each case enforceable against Exaeris in accordance with its terms,
                except
                as such enforceability may be limited by applicable bankruptcy,
                insolvency, moratorium, reorganization, or similar laws from time
                to time
                in effect which affect the enforcement of creditors' rights generally
                and
                by legal and equitable limitations on the availability of specific
                performance and other equitable remedies against Exaeris. All Persons
                who
                have executed this Agreement on behalf of Exaeris, or who will execute
                on
                behalf of Exaeris any agreement or instrument contemplated by this
                Agreement, have been duly authorized to do so by all necessary corporate
                action. Neither the execution and delivery of this Agreement by Exaeris,
                or any such other agreement or instrument by Exaeris, nor the performance
                of the obligations contemplated hereby and thereby, will (i) conflict
                with
                or result in any violation of or constitute a breach of any of the
                terms
                or provisions of, or result in the acceleration of any obligation
                under,
                or constitute a default under any provision of the Certificate of
                Incorporation or By-laws of Exaeris or any contract or any other
                obligation to which Exaeris is a party or to which it is subject
                or bound,
                or (ii) violate any judgment, order, injunction, decree or award
                of any
                court, administrative agency, arbitrator or government body against,
                or
                affecting or binding upon, Exaeris or upon the securities, property
                or
                business of Exaeris, or (iii) constitute a violation by Exaeris of
                any
                applicable law or regulation of any jurisdiction as such law or regulation
                relates to Exaeris or to the property or business of Exaeris except
                for
                such conflict, acceleration, default, breach or violation that is
                not
                reasonably likely to have a material adverse effect on Exaeris’ ability to
                perform its obligations under this Agreement or any agreement or
                instrument contemplated hereby

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        23

        
          

        

      

      
        
        

      

    

     

    
      	19.3  	
              TEAMM
                is a corporation duly organized and validly existing under the laws
                of the
                State of Florida. TEAMM has all necessary corporate power and authority
                to
                enter into, and be bound by the terms and conditions of this agreement.
                

            

    

    

    
      	19.4  	
              The
                execution, delivery and performance by TEAMM of this Agreement and
                each
                agreement of instrument contemplated by this Agreement and the performance
                of the transactions contemplated hereby and thereby, have been duly
                authorized by all necessary corporate action by TEAMM. This Agreement
                is,
                and each agreement or instrument contemplated by this Agreement,
                when
                executed and delivered by TEAMM in accordance with the provisions
                hereof,
                will be the legal, valid and binding obligation of TEAMM, in each
                case
                enforceable against TEAMM in accordance with its terms, except as
                such
                enforceability may be limited by applicable bankruptcy, insolvency,
                moratorium, reorganization, or similar laws from time to time in
                effect
                which affect the enforcement of creditors' rights generally and by
                legal
                and equitable limitations on the availability of specific performance
                and
                other equitable remedies against TEAMM. All Persons who have executed
                this
                Agreement on behalf of TEAMM, or who will execute on behalf of TEAMM
                any
                agreement or instrument contemplated by this Agreement, have been
                duly
                authorized to do so by all necessary corporate action. Neither the
                execution and delivery of this Agreement by TEAMM, or any such other
                agreement or instrument by TEAMM, nor the performance of the obligations
                contemplated hereby and thereby, will (i) conflict with or result
                in any
                violation of or constitute a breach of any of the terms or provisions
                of,
                or result in the acceleration of any obligation under, or constitute
                a
                default under any provision of the Certificate of Incorporation or
                By-laws
                of TEAMM or any contract or any other obligation to which TEAMM is
                a party
                or to which it is subject or bound, or (ii) violate any judgment,
                order,
                injunction, decree or award of any court, administrative agency,
                arbitrator or government body against, or affecting or binding upon,
                TEAMM
                or upon the securities, property or business of TEAMM, or (iii) constitute
                a violation by TEAMM of any applicable law or regulation of any
                jurisdiction as such law or regulation relates to TEAMM or to the
                property
                or business of TEAMM except for such conflict, acceleration, default,
                breach or violation that is not reasonably likely to have a material
                adverse effect on TEAMM’s ability to perform its obligations under this
                Agreement or any agreement or instrument contemplated
                hereby.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        24

        
          

        

      

      
        
        

      

    

     

    
      	19.5  	
              TEAMM
                hereby acknowledges that (i) TEAMM licenses the marketing rights
                to the
                Product in the United States under and pursuant to the terms and
                conditions of that certain Development and License Agreement by and
                between TEAMM and Respirics, and (ii) that Respirics has in turn
                authorized TEAMM to the market, sell and distribute the Products
                in the
                United States pursuant to the terms and conditions of the Respirics
                Marketing Agreement. 

            

    

    

    
      	19.6  	
              It
                is understood and agreed by TEAMM and Exaeris that TEAMM purchases
                the
                Product from a contract manufacturer controlled by Respirics, which
                is
                responsible for determining and insuring that all Product shall as
                of the
                date shipped to TEAMM, fully conform to the Specifications and have
                been
                manufactured in compliance with the 510(k) and all applicable laws.
                TEAMM
                makes no representation or warranty as to any product, expressed
                or
                implied, either in fact or by operation of law, by statue or otherwise,
                and TEAMM specifically disclaims any and all implied or statutory
                warranties, including without limitation, any warranty of fitness
                for a
                particular purpose or warranty of noninfringement.
                

            

    

     

    ARTICLE
      20

    MISCELLANEOUS

    

    
      	20.1  	
              Neither
                party shall assign this Agreement nor any of their respective rights
                or
                obligations hereunder without the prior written consent of the other
                party, except that either party may assign this Agreement to any
                of its
                Affiliates or to any Person or entity to which substantially all
                of its
                assets are transferred by operation of law or otherwise, including,
                but
                without limitation, by merger or transfer of stock. Any other attempted
                assignment without such consent shall be void. Any assignee or transferee
                of this Agreement and/or the rights or obligations hereunder shall
                expressly assume in writing all obligations of the assign or/transferor
                pursuant to this

            

    

    

    
      	20.2  	
              Notices.
                All notices or other communications required or permitted to be given
                hereunder shall be in writing and shall be deemed to have been duly
                given
                if delivered by hand or mailed first class, postage prepaid, by registered
                or certified mail, return receipt requested (notices shall be deemed
                to
                have been given on the date received) as
                follows:

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        25

        
          

        

      

      
        
        

      

    

     

            a.   
       If
      to
      Exaeris, as follows:

    Exaeris
      Pharmaceuticals, Inc.

    403
      Gordon Dr

    Exton,
      PA
      19341

    Attn
      to:
      Stephen Beckman

    

    With
      a
      copy to:

    Exaeris
      Pharmaceuticals, Inc.

    Attn:
      General Counsel

    

    
                              
        b.  If
        to
        TEAMM, as follows:

    

    

    TEAMM
      Pharmaceuticals, Inc

    2501
      Aerial Center Parkway

    Suite
      100

    Morrisville,
      NC 27560

    Attn
      to:
      Martin G. Baum

    

    With
      a
      copy to:

    Accentia
      Biopharmaceuticals, Inc. / TEAMM Pharmaceuticals, Inc

    

    324
      S.
      Hyde Park Avenue

    Tampa,
      FL
      33606

    Attn:
      General Counsel

    

    

    
      	c.  	
              or
                in any case to such other address or addresses as hereafter shall
                be
                furnished as provided in this article by any party hereto to the
                other
                party.

            

    

    

    
      	20.3  	
              Waiver:
                Remedies.
                No delay on the part of Exaeris or TEAMM in exercising any right,
                power or
                privilege hereunder shall operate as a waiver thereof, nor shall
                any
                waiver on the part of either Exaeris or TEAMM of any right, power
                or
                privilege hereunder operate as a waiver of any other right, power
                or
                privilege hereunder nor shall any single or partial exercise of any
                right,
                power or privilege hereunder preclude any other or further exercise
                thereof or the exercise of any other right, power or privilege hereunder.
                

            

    

    

    
      	20.4  	
              Entire
                Agreement.
                This Agreement and all agreements and documents referenced herein
                or
                contemplated hereby constitute the entire agreement between the parties
                with respect to the subject matter hereof and supersedes all prior
                agreements or understandings of the parties relating
                thereto.

            

    

    

    
      	20.5  	
              Amendment.
                This Agreement may be modified or amended only by written agreement
                of the
                parties hereto.

            

    

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        26

        
          

        

      

      
        
        

      

    

     

    
      	20.6  	
              Counterparts.
                This Agreement may be executed in any number of counterparts, each
                of
                which shall be deemed an original but all of which together shall
                constitute a single instrument.

            

    

    

    
      	20.7  	
              Governing
                Law.
                This Agreement shall be governed and construed in accordance with
                the laws
                of the State of Florida-excluding any choice of law rules which may
                direct
                the application of the law of another
                state.

            

    

    

    
      	20.8  	
              Captions.
                All section titles or captions contained in this Agreement, in any
                Article
                referred to herein or in any Exhibit annexed hereto, and the table
                of
                contents, if any, to this Agreement are for convenience only, shall
                not be
                deemed a part of this Agreement and shall not affect the meaning
                or
                interpretation of this Agreement.

            

    

    

    
      	20.9  	
              No
                Third Party Rights.
                No provision of this Agreement shall be deemed or construed in any
                way to
                result in the creation of any rights or obligations in any Person
                not a
                party to this Agreement

            

    

    

    
      	20.10  	
              Relationship
                of the Parties.
                Each party understands and agrees that it has no authority to assume
                any
                obligation on behalf of the other party and that, except as expressly
                permitted herein, it shall not hold out to third parties that it
                has any
                authority to act on the others party’s behalf (specifically with respect
                to any new buying customer, Exaeris may not bind TEAMM to any business
                arrangement whatsoever). Unless otherwise expressly stated herein,
                each
                party shall be responsible for its own expenses relating to its
                performance under the Agreement and shall not incur expenses for
                the other
                parties account unless expressly authorized in writing to do
                so.

            

    

    

    
      	20.11  	
              Headings.
                All headings are for reference purposes only and shall not in any
                way
                affect the meaning or interpretation of this
                Agreement.

            

    

    

    
      	20.12  	
              Severability.
                Both parties hereto expressly agree and contract that it is not the
                intention of either party to violate any public policy, statutory
                or
                common laws, rules, regulations, treaties or decisions of any government
                or agency thereof. If any provision of part thereof contained in
                this
                Agreement is declared invalid by any court of competent jurisdiction
                or a
                government agency having jurisdiction, each such declaration shall
                not
                affect the remainder of the provision or the other provisions and
                each
                shall remain in full force and effect.

            

    

    

    
      	20.13  	
              Force
                Majeure.
                If either party is prevented from complying, either totally or in
                part
                with any of the terms or provisions set forth herein, by reason of
                force
                majeure, including, by way of example and not of limitation, fire,
                flood,
                explosion, storm, strike, lockout or other labor dispute, riot, war,
                rebellion, accidents, acts of God, acts of governmental agencies
                or
                instrumentalities, failure of suppliers or any other external cause
                or
                externally induced casualty beyond its reasonable control, whether
                similar
                to the foregoing contingencies or not, said party shall provide written
                notice of same to the other party. Said notice shall be provided
                within
                three (3) business days of the occurrence of such event and shall
                identify
                the requirements of this Agreement or such of its obligations as
                may be
                affected, and to the extent so affected, said obligations shall be
                suspended during the period of such disability. The party prevented
                from
                performing hereunder shall use all commercially reasonable efforts
                to
                remove such disability, and shall continue performance whenever such
                causes are removed. The party so affected shall give to the other
                party a
                good faith estimate of the continuing effect of the force majeure
                condition and the duration of the affected party’s nonperformance. If the
                period of any previous actual nonperformance of Exaeris because of
                Exaeris
                force majeure conditions plus the anticipated future period of Exaeris
                nonperformance because of such conditions will exceed an aggregate
                of one
                hundred eighty (180) days within any twenty-four (24) month period,
                TEAMM
                may terminate this Agreement by written notice to Exaeris. If the
                period
                of any previous actual nonperformance of TEAMM because of TEAMM force
                majeure conditions plus the anticipated future period of TEAMM
                nonperformance because of such conditions will exceed an aggregate
                of one
                hundred eighty (180) days within any twenty-four (24) month period,
                Exaeris may terminate this Agreement by written notice to TEAMM.
                When such
                circumstances as those contemplated herein arise, the parties shall
                discuss in good faith, what, if any, modification of the terms set
                forth
                herein may be required in order to arrive at an equitable
                solution.

            

    

    

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        27

        
          

        

      

      
        
        

      

    

    

    IN
      WITNESS WHEREOF,
      the
      parties have caused this Agreement to be duty executed and delivered on the
      day
      and year first above written.

    

    
      	 	 	 	 
	TEAMM Pharmaceuticals,
              Inc. 	Accentia
              Biopharmaceuticals, Inc
	 	 
 	 
 	 
 
	 By: 	 /s/
              Martin G. Baum  	By:  	 /s/
              Frank O’Donnell, Jr.
	 	 Martin
              G. Baum	Frank O’Donnell, Jr., MD
	 	 President
              and Chief Operating Officer	Chairman
	 	 	 
	Exaeris, Inc	 
	 By:	 /s
              / Stephen Beckman	 
	 	Stephen
              Beckman
              President
                and Chief Operating Officer

            	 

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        28

        
          

        

      

      
        
        

      

    

       

    EXHIBIT
      1

    

    Example
      of Compensation Calculation

    

    

    ***

     

     

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
 

    EXHIBIT
      2

    

    

    

    

    

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    EXHIBIT
      3

    

    

    Format
      to submit physician data for inclusion into Prescriber Data Source and
      Prescriber List

    

    Excel
      Spreadsheet

    

      
        	
                ME
                  Number

              	 	 	
                Last
                  Name

              	 	 	
                First
                  Name

              	 	 	
                Middle
                  Initial

              	 	 	
                Street
                  Address

              	 	 	
                City

              	 	 	
                State
                  

              	 	 	
                Zip
                  Code

              	 	 	
                Specialty

              	 	 	
                Territory
                  number

              	 

      

    

    

    
      
        CONFIDENTIAL
          TREATMENT

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    

    EXHIBIT
      4

    

    EXAMPLE:
      Calculation of Co-Promotion Payment to Exaeris

    

    

    ***

     

     

    
      
        CONFIDENTIAL
          TREATMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]